Skip to main content

Table 2 Risk of cancer after SLE cohort entry compared to general population controls (N = 2431 SLE patients contributing 20,399 person-years)#

From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection

Site

No. obs.

No. exp.

SLE cohort SIR (95%CI)

p value

AA* SIR (95%CI)

AA p value

Non-AA^ SIR (95%CI)

Non-AA p value

All

119

102.3

1.16 (0.96–1.39)

0.12

1.63 (1.26–2.08)

< 0.001

0.86 (0.65–1.13)

0.31

Female cancers

 Breast

22

34.9

0.63 (0.39–0.95)

0.027

1.13 (0.65–1.84)

0.69

0.29 (0.11–0.63)

< 0.001

 Cervix

11

4

2.73 (1.36–4.89)

0.006

3.78 (1.52–7.79)

0.006

1.84 (0.50–4.71)

0.35

 Vagina/vulva

13

1.9

6.87 (3.66–11.8)

< 0.001

14.13 (7.05–25.3)

< 0.001

1.80 (0.22–6.49)

0.61

Other cancers

 Hematologic

10

6.5

1.54 (0.74–2.84)

0.24

1.87 (0.61–4.36)

0.27

1.31 (0.43–3.07)

0.67

 Lung

11

8.7

1.27 (0.63–2.26)

0.52

1.84 (0.74–3.80)

0.18

0.82 (0.22–2.09)

0.92

 Colorectal

10

7.2

1.39 (0.66–2.55)

0.38

1.18 (0.32–3.01)

0.88

1.57 (0.58–3.42)

0.37

 Thyroid

9

4

2.27 (1.04–4.30)

0.041

0.00 (0–3.31)

0.66

3.15 (1.44–5.98)

0.006

 Melanoma

8

5.4

1.48 (0.64–2.91)

0.36

0.00 (0–37.3)

0.99

1.51 (0.65–2.97)

0.34

HPV-associated cancers**

26

5.9

4.39 (2.87–6.44)

< 0.001

7.23 (4.35–11.3)

< 0.001

2.13 (0.86–4.38)

0.10

  1. Data for cancer sites with < 5 cases observed after cohort entry are not presented, including the uterus, ovary, fallopian tube, prostate, multiple myeloma, salivary gland, stomach, duodenal and other small bowel, anus, pancreas, liver, kidney, bladder, brain, and unknown primary
  2. **HPV-associated cancers include cervix, vulva/vagina, and anus cancers
  3. AA = African American; non-AA = non-African American
  4. *N = 966 SLE patients contributing 8488 person-years
  5. ^N = 1465 SLE patients contributing 11,911 person-years
  6. #When adjusting for multiple comparisons (10 per racial strata), p ≤ 0.005 is considered statistically significant